Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder Clinical Trial

Official title:

Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01218789
• Other study ID #: VP-VEC-162-3202
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 28, 2010
• Est. completion date: December 5, 2024

Study information

• Verified date: April 2024
• Source: Vanda Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.

Description:

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, open-label study. The study has two phases: the screening phase and the evaluation phase. The screening phase is comprised of a screening visit where a patient's general health and initial eligibility will be evaluated. The evaluation phase is comprised of a baseline visit and a 52 week segment. Patients that meet all entry criteria for the study at baseline visit will enter the treatment segment where patients will be asked to take 20 mg tasimelteon daily approximately 60 minutes prior to their target bedtime for 52 weeks in an open-label fashion. An optional sub-study extension phase is available to subjects who complete the first year of treatment and consists of continued open-label treatment for up to 3 years additional.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 140
• Est. completion date: December 5, 2024
• Est. primary completion date: December 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Ability and acceptance to provide informed consent;

• No perception of light;

• History (within the last 3 months) of trouble sleeping at night difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire

• Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;

Exclusion Criteria:

• Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;

• Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;

• History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;

• History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;

• Smoke more than 10 cigarettes/day

• Participation in a previous tasimelteon (aka VEC-162 or BMS-214778) trial;

• Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle within 3 weeks or 5 half-lives (whichever was longer) of Baseline;

• Use of melatonin or melatonin agonist;

Related Conditions & MeSH terms

• Non 24 Hour Sleep Wake Disorder
• Sleep Disorders, Circadian Rhythm
• Sleep Wake Disorders

Intervention

Drug:
• tasimelteon
20 mg tasimelteon capsules, PO daily for 1 year

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Vanda Pharmaceuticals

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 4
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 8
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 12
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 16
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 26
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 34
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 42
Primary	Safety Evaluations	the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).; The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.	Week 52
Secondary	Patient Global Impression of Change (PGI-C)	A patient rated assessment of reported nighttime sleep	Weeks 8, 16, 26, 34, 42, 52
Secondary	Clinical Global Impression of Change (CGI-C)	rate of total improvement due to drug as viewed by the clinician	Weeks 8, 16, 26, 34, 42, 52
Secondary	Patient Global Impression of Change (PGI-C)	A patient rated assessment on daytime naps	Weeks 8, 16, 26, 34, 42, 52